Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database
Abstract Background As a novel anti-influenza agent, baloxavir marboxil lacks real-world safety data in large populations. Therefore, this study aimed to investigate adverse drug events (ADEs) associated with baloxavir marboxil by analyzing the Food and Drug Administration Adverse Event Reporting Sy...
Saved in:
| Main Authors: | Xiaolong Lai, Liuyin Jin, Yixia Zhou, Yang Li, Lindan Sheng, Guomin Xie, Jianjiang Fang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Pharmacology and Toxicology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40360-025-00940-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza
by: Jiali Jiang, et al.
Published: (2025-07-01) -
Validation of chromatographic method for impurity profiling of Baloxavir marboxil (Xofluza)
by: Wang Yiyun, et al.
Published: (2025-03-01) -
Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024
by: Emi Takashita, et al.
Published: (2025-05-01) -
Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
by: Amira S. Gouda, et al.
Published: (2025-01-01) -
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)